September 28, 2022
Throughout the pandemic, rheumatologists have been concerned that their patients may be at risk of developing more severe forms of the COVID-19 disease as a result of their rheumatic disease or treatment.
May 05, 2022
According to investigators, pulmonary hypertension indicates an increased risk of mortality in patients with systemic sclerosis.
April 28, 2022
“In recent years, the habit of delaying pregnancy because of social and economic reasons has become more common, increasing the possibility of getting pregnant after the onset of the disease," investigators stated. "This fact makes pregnancy a more frequent issue to deal with in the present years.”
March 23, 2022
A retrospective study analyzed patients with systemic sclerosis to determine prevalence, severity, and mortality within this patient population.
November 22, 2021
Robert F Spiera, MD, explains background mycophenolate treatment and its associated improved outcomes in patients with systemic sclerosis receiving lenabasum.
April 30, 2021
The SPIN-CHAT Program was developed by investigators in order to help participants deal with isolation and learn better mental health coping mechanisms.
March 09, 2021
Subcutaneous injection of tocilizumab has been shown to improve the rate of lung function in patients with systemic sclerosis-induced interstitial lung disease when compared with a placebo.
September 28, 2020
Autologous hematopoietic stem cell transplants (AHSCT) improve the quality of life in patients with systemic sclerosis (SSc), researchers say.
November 18, 2019
Patients who have systemic sclerosis-associated interstitial lung disease and received nintedanib were more likely to have improved lung function than patients who received a placebo, according to a new study. Not only did nintedanib improve forced vital capacity, but patients who received the drug were less likely to experience declining clinical status and more likely to see their conditions stabilize.
September 12, 2019
A proof of concept clinical trial for riociguat (Adempas, Bayer) for patients with systemic sclerosis indicates that longer treatment periods may be necessary to heal digital ulcers. In this trial, the treatment wasn't effective in reducing the number of digital ulcers.